43672
LBX PHARMACY CHAIN JSC
Aug 13, 2020
China
East Asia and the Pacific
Jun 12, 2021
B - Limited
Active
Approved : Oct 1, 2020
Signed : Oct 30, 2020
Invested : Mar 31, 2021
other
Health, Education and Life Sciences
Regional Industry - MAS Asia & Pac
The Laobaixing Pharmacy Chain Joint Stock Company (“LBX” or the “company” - http://www.lbxdrugs.com/) is listed on the Shanghai Stock Exchange and is a leading pharmaceutical retailer with stores across 22 provinces in China. The company has three business store units: direct stores (100% owned); Spark Business group stores (51-67% equity ownership) and franchised stores. The company also owns an in-house logistics operator (Fengwoda) and Yaoshengtang Pharmaceutical Company which integrates traditional Chinese medical production manufacture and scientific research.
As of March 31, 2020, LBX operates around 4,100 direct-sale stores including Spark Business group stores and 1,400 franchise stores. The company also operates a state-of-the-art national logistics center in Changsha, Hunan along with 4 regional logistics centers and 22 provincial distribution centers, and effectively manage inventory through advanced warehousing management systems such as automatic assortment lines, automatic labeling and shelfing.
The Company plans to add over 2,500 stores as well as 5 new logistics centers within the next 3 years (The Project). The proposed IFC investment is a senior loan of RMB 1,000 million (approximately $142 million equivalent) to support the expansion of stores and the new logistics centers.
IFC’s review of the proposed investment consisted of appraising environmental, health and safety (EHS) and social information submitted by LBX including; i) group business details and expansion plans; ii) corporate policies and procedures including that related to quality control, emergency responses, Human Resources (HR) management; iii) monitoring and audit reports; and iv) information, documents, pictures and videos made available by the company related to the company’s operation and environmental and social (E&S) performance.
In addition, meetings were convened with the company’s senior management, and those responsible for quality management and HR via video conferencing to understand the company’s operations and the expansion plan.
It should be acknowledged that given travel restrictions due to COVID-19, it was not possible to undertake a site visit. Following the lifting of travel restrictions, IFC will visit the company as part of the regular portfolio monitoring activities to confirm the findings as identified in this Environmental and Social Review Summary document.